ISORAY, INC. (NYSEMKT:ISR) Files An 8-K Entry into a Material Definitive Agreement

ISORAY, INC. (NYSEMKT:ISR) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

ITEM 1.01

Entry into a Material Definitive Agreement

On December 22, 2016, IsoRay Medical, Inc. (Medical), a wholly
owned subsidiary of IsoRay, Inc. (the Registrant), entered into
Addendum No. 1 (the Addendum) to its supply contract (the
Agreement) with The Open Joint Stock Company Isotope, a Russian
company (JSC Isotope). With the Addendum, Medical will purchase
Cesium-131 manufactured by Joint Stock Company Institute of
Nuclear Materials and sold by JSC Isotope, within the quality
standards and within the time periods specified, through December
31, 2017 rather than March 31, 2017 as provided in the Agreement.

ITEM 9.01 Financial Statements and Exhibits
(c) Exhibits
10.1 Addendum No. 1 to Contract, dated December 22, 2016 and
effective as of December 9, 2016, by and between IsoRay
Medical, Inc. and The Open Joint Stock Company Isotope
(confidential treatment requested for redacted portions)


IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company’s Proxcelan Cesium-131 seed is classified as a Class II device.

ISORAY, INC. (NYSEMKT:ISR) Recent Trading Information

ISORAY, INC. (NYSEMKT:ISR) closed its last trading session down -0.033 at 0.640 with 134,408 shares trading hands.

An ad to help with our costs